In conclusion, we found in this population of patients with small HER2-positive breast cancers that during treatment with adjuvant T-DM1 the incidence of grade 3–4 LVSD (symptomatic HF) and significant asymptomatic decreases in LVEF were low: both rates were 0.8%. This evidence concerns the gene ERBB2 and breast carcinoma.